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years for related and unrelated recipients, respectively. Two
year overall survival was 42% and disease-free survival was 36%,
with disease stages and cytogenetic risks being major determi-
nants for outcome. Patients transplanted in CR1 had 2-year
overall survivals of 40% after related and 57% after unrelated
HCT. We conclude that HCT from related and unrelated
donors after low-dose TBI is a promising treatment for elderly
patients and medically inﬁrm younger patients with AML not
eligible for conventional HCT.
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FEWER EARLY BACTERIAL AND VIRAL INFECTIONS FOLLOWING NON-
MYELOABLATIVE VS. MYELOABLATIVE CONDITIONING FOR ALLO-
TRANSPLANTATION
Bachanova, V., Brunstein, C., Burns, L.J., Miller, J.S., Tan, Y.,
van Burik, J., Weisdorf, D., Tomblyn, M. University of Minnesota, Divi-
sion of Hematology, Oncology, and Transplantation, Minneapolis, MN.
To examine the incidence and timing of infectious complications,
we reviewed 141 consecutive lymphoma patients receiving allogeneic
hematopoietic stem cell transplantation using either myeloablative
(MA) (n  65) or non-myeloablative (NMA) (n  76) conditioning.
The NMA cohort was older (48.4 vs 41.4 years, P .01), more often
given unrelated umbilical cord blood as a stem cell source (43% vs
9%, P .01), had comparable CMV seropositivity (39% vs 49%) and
39% had received a prior autologous transplant. All patients received
antimicrobial prophylaxis including an extended spectrum ﬂuoroquin-
olone, ﬂuconazole, and acyclovir in addition to weekly CMV surveil-
lance. The time to initial infection was determined for each patient to
analyze potential differences in types and time to onset of infection
between the cohorts. For this, patients were evaluated once in each of
three microbial categories bacterial, viral, and fungal (Table 1). Fatal
infections were uncommon and the incidence was similar in the MA
and NMA cohorts [MA: 12 (18%); NMA: 12 (16%)]. In the peri-
transplant period (day 0-30), the MA cohort had 2.2-fold greater
primary bacterial infections, but the risks of initial bacterial infection
were similar in the early (day 31-100) and late (day 101-365) post
transplant periods. Viral infections were twice as frequent in the MA
cohort during the peritransplant period though similar from day
30-100. Beyond day 100, the MA cohort again had 2-fold greater
primary viral infections. Fungal infections developed in approximately
10% of patients in both cohorts and the risks were similar during all
three time periods. These data demonstrate a signiﬁcantly greater
incidence of bacterial and viral peri-transplant infections using MA
conditioning though infectious mortality was similar using either
conditioning. Quicker engraftment and shorter periods of neutrope-
nia may explain in part the reduced incidence of initial peri-transplant
bacterial infections in the NMA cohort, but the pathophysiology
underlying the later infectious risks is uncertain. Immune reconstitu-
tion is delayed after both MA and NMA conditioning but protection
against infection appears similar using either treatment approach.
Future studies to correlate immune reconstitution with infections are
required to identify patients at greatest risk of later infections and to
design new strategies for their prevention.
Table 1. Incidence of Infections
Myeloablative Non-myeloablative P-Value
Bacterial
Day 0–30 49% (36–62) 22% (13–32) <.01
Day 31–100 47% (28–66) 48% (35–62) NS
Day 101–365 23% (0–45) 11% (0–22) NS
Viral
Day 0–30 18% (9–28) 9% (3–16) .08
Day 31–100 31% (17–45) 44% (32–56) NS
Day 101–365 44% (25–64) 21% (7–35) .05
Fungal
Day 0–30 12% (4–21) 9% (3–16) NS
Day 31–100 12% (3–21) 13% (5–22) NS
Day 101–365 10% (1–20) 17% (7–28) NS
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO HCT)
FOR METASTATIC BREAST CANCER (MBC)
Ueno, N.T.1, Rizzo, J.D.2, Cheng, Y.C.2, Childs, R.3, Stiff, P.J.3,
Demirer, T.4, Horowitz, M.M.2, Niederwieser, D.4 1The University of
Texas M.D. Anderson Cancer Center, Houston, TX; 2Medical College of
Wisconsin, Milwaukee, WI; 3Center for International Blood and Mar-
row Transplant Research (CIBMTR); 4The European Group for Blood
and Marrow Transplantation (EBMT).
We reviewed data on women who received allogeneic hema-
topoietic cell transplantation (HCT) for metastatic breast can-
cer at 16 centers participating in the CIBMTR and the EBMT
between 1992 and 2000. Probabilities of transplant-related mor-
tality (TRM), graft-vs-host disease (GVHD), disease relapse or
progression, progression-free survival (PFS), and overall sur-
vival were determined. Seventy-ﬁve patients were identiﬁed;
median age at transplantation was 41 years (range, 25-60).
Median follow-up time for survivors was 25 months (range,
3-64). Thirty-nine patients (52%) received myeloablative con-
ditioning regimens and 36 (48%) received reduced-intensity
conditioning (RIC) regimens. Nine of the RIC patients were
treated with a planned tandem autologous-allogeneic approach.
Patient characteristics were similar between the two groups
except that more patients in the RIC group (72%) had poor
pretransplant performance status than in the myeloablative
group (28%). More patients in the myeloablative group devel-
oped acute GVHD (44% vs 34% at 100 days), chronic GVHD
(36% vs. 8% at one year) and TRM (29% vs 7% at 100 days)
compared to RIC. Overall response rates (complete or partial
response) were 31% in the myeloablative group and 29% in the
RIC group. Eleven of 42 patients (26%) who underwent im-
mune manipulation (withdrawal of immunosuppression and/or
donor lymphocyte infusion) after transplantation had disease
control (complete, partial, minor, or stable response), providing
evidence of a graft-vs-tumor (GVT) effect. Overall survival at 2
yrs was 24% (15-35%) for all patients. PFS at 1 year was 23%
for myeloablative patients and 8% for RIC (excludes planned
tandem) patients. Development of acute GVHD after an RIC
regimen compared to no GVHD reduced the risk of relapse or
progression (RR 3.05, P  .03) in multivariate analysis, consis-
tent with a GVT effect, but this did not affect PFS. These
ﬁndings support development of innovative allotransplantation
approaches to exploit GVT effects for disease control while
minimizing TRM. Planned tandem autologous-allogeneic RIC
HCT, where probabilities of TRM and PFS at 2 years were 11%
and 44% respectively for a small number of patients in these
data, may represent such an alternative approach.
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HAEMOPOIETIC STEM CELL TRANSPLANTS FOR CHRONIC MYELOFI-
BROSIS—A REVIEW FROM THE ABMTRR
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Durrant, S.4,
Ma, D.D.F.3, Szer, J.5 1Australasian Bone Marrow Transplant Recip-
ient Registry (ABMTRR), Darlinghurst, NSW, Australia; 2Westmead
Hospital, Westmead, NSW, Australia; 3St. Vincent’s Hospital, Darlin-
ghurst, NSW, Australia; 4Royal Brisbane Hospital, Brisbane, Queens-
land, Australia; 5Royal Melbourne Hospital, Parkville, Victoria, Aus-
tralia.
The Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR) has been recording activity and outcome data for
haemopoietic stem cell transplants in Australia since 1992 and New
Zealand since 1998. Between 1992 and 2004 there were 50 hae-
mopoietic stem cell transplants for chronic myeloﬁbrosis in Aus-
tralia and 1 in New Zealand. Of these, 46 were allogeneic, 3
syngeneic and 2 autologous; 35 were male and 16 were female. The
median age at transplant was 48 with a range of 16 to 71. The
annual number of transplants for this indication is small but in-
creasing. In the ﬁve years 2000 to 2004, there were 33 transplants
for this indication compared to 14 in 1995-1999. Of the donors for
allogeneic transplants, 33 were HLA-identical siblings, 3 were
siblings or other relatives with 1 HLA mismatch and 10 were
unrelated volunteers. Within the allogeneic transplants performed
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